Abstract: About 30% of differentiated thyroid carcinoma(DTC) loses its ability of differentiation, which results in poor or no effect of the radioiodine therapy and the thyroid hormone replacement therapy after operation. Retinoic acids, the biologically active metabolite of vitamin A, is of central importance for growth, proliferation and differentiation of various cells. In this review, summarized the mechanism of the dedifferentiation among the DTC, the retinoic acids-induced redifferention and the clinical use of retinoic acids. It is demonstrated by many studies that retinoic acids-induced redifferentiaon has a large potential in the treatment of DTC.